PATENT ROW

  • 'Has to be a balance between innovation, affordability of drugs' April 1, 2013

    After the Supreme Court dismissed Swiss pharma company Novartis' plea for a patent on its cancer drug Glivec, pharma expert vikas Dandekar said, "This will be a far reaching decision. Innovation on one side, access and affordability on the other side. The balance has to be done". ...